Willemse Eline A J, Teunissen Charlotte E
Neurochemistry Laboratory and Biobank, Department of Clinical Chemistry, VU University Medical Center Amsterdam, Neuroscience Campus Amsterdam, 7057, Amsterdam, 1007 MB, The Netherlands.
Adv Exp Med Biol. 2015;864:79-93. doi: 10.1007/978-3-319-20579-3_7.
Cerebrospinal fluid (CSF) reflects pathophysiological aspects of neurological diseases, where neuroprotective strategies and biomarkers are urgently needed. Therefore, biobanking is very relevant for biomarker discovery and evaluation for these neurological diseases.An important aspect of CSF biobanking is quality control, needed for e.g. consistent patient follow-up and the exchange of patient samples between research centers. Systematic studies to address effects of pre-analytical and storage variation on a broad range of CSF proteins are needed and initiated.Important features of CSF biobanking are intensive collaboration in international networks and the tight application of standardized protocols. The current adoption of standardized protocols for CSF and blood collection and for biobanking of these samples, as presented in this chapter, enables biomarker studies in large cohorts of patients and controls.In conclusion, biomarker research in neurodegenerative diseases has entered a new era due to the collaborative and multicenter efforts of many groups. The streamlining of biobanking procedures, including sample collection, quality control, and the selection of optimal control groups for investigating biomarkers is an important improvement to perform high quality biomarker studies.
脑脊液(CSF)反映了神经疾病的病理生理方面,而目前迫切需要神经保护策略和生物标志物。因此,生物样本库对于这些神经疾病的生物标志物发现和评估非常重要。脑脊液生物样本库的一个重要方面是质量控制,这对于例如持续的患者随访以及研究中心之间患者样本的交换是必要的。需要并已启动系统性研究,以探讨分析前和储存变异对多种脑脊液蛋白质的影响。脑脊液生物样本库的重要特征包括国际网络中的密切合作以及标准化方案的严格应用。本章介绍的当前脑脊液和血液采集以及这些样本生物样本库的标准化方案的采用,使得能够在大量患者和对照人群中开展生物标志物研究。总之,由于许多团队的协作和多中心努力,神经退行性疾病的生物标志物研究已进入一个新时代。生物样本库程序的简化,包括样本采集、质量控制以及为研究生物标志物选择最佳对照组,是开展高质量生物标志物研究的一项重要改进。